These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 23384679

  • 1. The novel TLR-9 agonist QbG10 shows clinical efficacy in persistent allergic asthma.
    Beeh KM, Kanniess F, Wagner F, Schilder C, Naudts I, Hammann-Haenni A, Willers J, Stocker H, Mueller P, Bachmann MF, Renner WA.
    J Allergy Clin Immunol; 2013 Mar; 131(3):866-74. PubMed ID: 23384679
    [Abstract] [Full Text] [Related]

  • 2. Assessment of clinical efficacy of CYT003-QbG10 in patients with allergic rhinoconjunctivitis: a phase IIb study.
    Klimek L, Willers J, Hammann-Haenni A, Pfaar O, Stocker H, Mueller P, Renner WA, Bachmann MF.
    Clin Exp Allergy; 2011 Sep; 41(9):1305-12. PubMed ID: 21672053
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Omalizumab is effective in the long-term control of severe allergic asthma.
    Lanier BQ, Corren J, Lumry W, Liu J, Fowler-Taylor A, Gupta N.
    Ann Allergy Asthma Immunol; 2003 Aug; 91(2):154-9. PubMed ID: 12952109
    [Abstract] [Full Text] [Related]

  • 8. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study.
    Niven R, Chung KF, Panahloo Z, Blogg M, Ayre G.
    Respir Med; 2008 Oct; 102(10):1371-8. PubMed ID: 18657960
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma.
    Berger W, Gupta N, McAlary M, Fowler-Taylor A.
    Ann Allergy Asthma Immunol; 2003 Aug; 91(2):182-8. PubMed ID: 12952113
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. CYT003, a TLR9 agonist, in persistent allergic asthma - a randomized placebo-controlled Phase 2b study.
    Casale TB, Cole J, Beck E, Vogelmeier CF, Willers J, Lassen C, Hammann-Haenni A, Trokan L, Saudan P, Wechsler ME.
    Allergy; 2015 Sep; 70(9):1160-8. PubMed ID: 26042362
    [Abstract] [Full Text] [Related]

  • 14. Comparative clinical study of inhaled beclomethasone dipropionate and triamcinolone acetonide in persistent asthma.
    Bronsky E, Korenblat P, Harris AG, Chen R.
    Ann Allergy Asthma Immunol; 1998 Apr; 80(4):295-302. PubMed ID: 9564977
    [Abstract] [Full Text] [Related]

  • 15. Treatment of asthma with nebulized lidocaine: a randomized, placebo-controlled study.
    Hunt LW, Frigas E, Butterfield JH, Kita H, Blomgren J, Dunnette SL, Offord KP, Gleich GJ.
    J Allergy Clin Immunol; 2004 May; 113(5):853-9. PubMed ID: 15131566
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Effects of H1 blocker and inhaled corticosteroids on asthmatic patients with allergic rhinitis].
    He WQ, Zheng JP, Ran PX, Liu HZ, Lin H, Cai DM, Xu JM, Zhong NS.
    Zhonghua Jie He He Hu Xi Za Zhi; 2003 Mar; 26(3):157-60. PubMed ID: 12816681
    [Abstract] [Full Text] [Related]

  • 18. Tolerability of indacaterol, a novel once-daily beta2-agonist, in patients with asthma: a randomized, placebo-controlled, 28-day safety study.
    Yang WH, Martinot JB, Pohunek P, Beier J, Magula D, Cameron R, Owen R, Higgins M.
    Ann Allergy Asthma Immunol; 2007 Dec; 99(6):555-61. PubMed ID: 18219838
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Montelukast or salmeterol combined with an inhaled steroid in adult asthma: design and rationale of a randomized, double-blind comparative study (the IMPACT Investigation of Montelukast as a Partner Agent for Complementary Therapy-trial).
    Bjermer L, Bisgaard H, Bousquet J, Fabbri LM, Greening A, Haahtela T, Holgate ST, Picado C, Leff JA.
    Respir Med; 2000 Jun; 94(6):612-21. PubMed ID: 10921768
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.